Altimmune abandons ship on intranasal Covid-19 vaccine, refocusing on liver, obesity programs after trial flop
Among the also-rans in the Covid-19 vaccine race, small biotech Altimmune hoped to ride a novel intranasal formulation for its own candidate to market but ran into an FDA clinical hold along the way. Now, after the vaccine turned out a dud in an early-stage test, Altimmune is bailing out and refocusing around its other programs.
Altimmune’s single-dose vaccine, dubbed AdCOVID, didn’t spur an adequate immune response in a Phase I test in 80 healthy volunteers, the biotech said Tuesday. Meanwhile, the vaccine was well tolerated, but the lack of results was good enough for Altimmune to walk away.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
